Intech Investment Management LLC Makes New $172,000 Investment in Aura Biosciences, Inc. (NASDAQ:AURA)

Intech Investment Management LLC purchased a new position in Aura Biosciences, Inc. (NASDAQ:AURA) in the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor purchased 20,926 shares of the company’s stock, valued at approximately $172,000.

A number of other hedge funds also recently modified their holdings of the business. China Universal Asset Management Co. Ltd. acquired a new position in shares of Aura Biosciences in the 4th quarter valued at approximately $87,000. AlphaQuest LLC acquired a new position in shares of Aura Biosciences in the fourth quarter valued at approximately $136,000. JPMorgan Chase & Co. increased its position in shares of Aura Biosciences by 107.5% during the third quarter. JPMorgan Chase & Co. now owns 53,502 shares of the company’s stock worth $477,000 after acquiring an additional 27,718 shares in the last quarter. Barclays PLC raised its holdings in shares of Aura Biosciences by 256.5% during the third quarter. Barclays PLC now owns 61,010 shares of the company’s stock worth $544,000 after acquiring an additional 43,897 shares during the period. Finally, Wellington Management Group LLP bought a new stake in Aura Biosciences in the 3rd quarter valued at $1,037,000. Institutional investors and hedge funds own 96.75% of the company’s stock.

Insider Transactions at Aura Biosciences

In other news, insider Los Pinos Elisabet De sold 15,955 shares of Aura Biosciences stock in a transaction dated Tuesday, January 21st. The shares were sold at an average price of $7.67, for a total value of $122,374.85. Following the completion of the transaction, the insider now owns 304,692 shares of the company’s stock, valued at $2,336,987.64. This trade represents a 4.98 % decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. Insiders have sold a total of 23,045 shares of company stock worth $177,242 in the last 90 days. Corporate insiders own 5.40% of the company’s stock.

Wall Street Analyst Weigh In

AURA has been the subject of a number of research reports. HC Wainwright reiterated a “buy” rating and set a $22.00 target price on shares of Aura Biosciences in a report on Monday. Lifesci Capital raised Aura Biosciences to a “strong-buy” rating in a research report on Friday, January 31st. Five equities research analysts have rated the stock with a buy rating and two have issued a strong buy rating to the company’s stock. According to data from MarketBeat, Aura Biosciences has an average rating of “Buy” and a consensus target price of $23.00.

Aura Biosciences Price Performance

Shares of NASDAQ:AURA opened at $5.94 on Friday. The company’s 50-day moving average price is $7.57 and its two-hundred day moving average price is $8.62. Aura Biosciences, Inc. has a one year low of $5.77 and a one year high of $12.38. The stock has a market capitalization of $296.71 million, a PE ratio of -3.43 and a beta of 0.30.

Aura Biosciences (NASDAQ:AURA) last released its earnings results on Monday, March 24th. The company reported ($0.52) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.43) by ($0.09). On average, analysts anticipate that Aura Biosciences, Inc. will post -1.66 earnings per share for the current fiscal year.

Aura Biosciences Company Profile

Aura Biosciences, Inc, a clinical-stage biotechnology company, develops precision immunotherapies to treat a range of solid tumors. The company's proprietary platform enables the targeting of a range of solid tumors using virus-like particles conjugated with drugs or loaded with nucleic acids to create virus-like drug conjugates.